← Back to Clinical Trials
Recruiting NCT00260585

Esophageal Cancer Risk Registry

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Esophageal Cancer
Sponsor University of Pittsburgh
Study Type OBSERVATIONAL
Phase N/A
Enrollment 7,000
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 1999-06
Completion 2050-12
Interventions
Survey of client health, personal habits, family historyBlood specimen for non-DNA and DNA partsBiopsy of esophageal/stomach tissue, lymph nodes, tumor

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The purpose of this study is to identify markers in the blood and tissue that could indicate risk factors for the development and progression of esophagus cancer. This research aims to collect medical history, blood, and tissue samples from patients who present with an esophageal disorder. Identifying genetic and behavioral risk factors involved in the development of esophageal cancer might allow for early detection and prevention. Survival and an opportunity for a cure with esophageal cancer will depend greatly on the stage of diagnosis. Tumors can develop changes in their genetic (hereditary) make-up, and these changes can sometimes be seen in normal tissues before the development of cancer. These genetic (hereditary) changes can serve as tumor markers and can be detected using methods that study changes in genetic material like DNA and RNA. The analysis of proteins can provide additional information. By identifying changes in these molecules that are different or altered in cancer, the investigators can use methods and tests for the detection of these changes.

Eligibility Criteria

Inclusion Criteria: * Known or suspected esophageal or gastroesophageal junction malignancy * Known Barrett's metaplasia * Clinical management of symptomatic gastroesophageal reflux disease (GERD) * Achalasia * Hiatal hernia Exclusion Criteria: * Elevated pre-operative bloodwork will not have the additional biopsies taken. * Platelet count less than 150,000, partial thromboplastin time (PTT) of 50 or above, and/or International Normalized Ratio (INR) of 1.8 or above will not have the additional biopsies taken.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}